Search

Displaying results 3671 - 3680 of 10000 in total
  1. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility

  2. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult … SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha).

  3. Drug

    Probenecid

    go.drugbank.com/drugs/DB01032
    ApprovedInvestigational

    Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. … It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.

    Categories: Topoisomerase II Inhibitors
  5. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. … Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics.

  6. Drug

    Corynebacterium diphtheriae

    go.drugbank.com/drugs/DB09877
    ApprovedInvestigational

    The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered. … The vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children.

    Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, Boostrix Polio - Injektionssuspension in einer Fertigspritze
  7. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history … By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

    Categories: Protease-activated Receptor-1 Antagonist, Protease-activated Receptor-1 Antagonists
  8. Drug

    Artesunate

    go.drugbank.com/drugs/DB09274
    ApprovedInvestigational

    Artesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria.

  9. Drug

    Cenisertib

    go.drugbank.com/drugs/DB06347
    Investigational

    Cenisertib is an aurora kinase inhibitor.

  10. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.

    Categories: Endothelin Receptor Antagonists, Endothelin A Receptor Antagonists